Market Overview

Corindus Receives FDA Clearance for First Automated Robotic Movement in technIQ™ Series for CorPath GRX Platform

Share:

Procedural Automation Software Designed to Facilitate Advanced
Guidewire Navigation

Corindus Vascular Robotics, Inc. (NYSE:CVRS), a leading
developer of precision vascular robotics, announced today that it
received 510(k) clearance from the U.S. Food and Drug Administration
(FDA) for the first automated robotic movement designed for the CorPath
GRX platform.

The proprietary software feature, named "Rotate on Retract" (RoR), is
the first automated robotic movement in the technIQ Series for the
CorPath GRX platform. It allows the operator to quickly navigate to a
targeted lesion by automatically rotating the guidewire upon joystick
retraction. Preclinical data presented at the Transcatheter
Cardiovascular Therapeutics (TCT) Conference in October 2017
demonstrated a significant reduction in wiring time among a
highly-experienced group of physicians when comparing robotic wiring
versus robotic wiring with RoR enabled.

Following the software's CE Mark approval in January 2018,
interventional cardiologists Arif Al Nooryani, M.D. and Wael Aboushokka,
M.D. of Al Qassimi Hospital in Sharjah, Dubai, UAE, performed the first
percutaneous coronary interventional procedures (PCI) in the world using
RoR. Today Nelson Bernardo, M.D., Medical Director of the Peripheral
Vascular Laboratory at MedStar Heart Institute, will be performing a
robotic-assisted peripheral intervention utilizing RoR, which will be
broadcast live to the Cardiovascular Research Technologies (CRT) Meeting
in Washington, D.C.

"This first-of-its-kind automation software has the potential to extend
the clinical capabilities of CorPath GRX in more complex procedures,"
said J. Aaron Grantham, M.D., Chief Medical Officer of Corindus and
practicing Interventional Cardiologist at Saint Luke's Mid America Heart
Institute. "Bringing consistency to interventional procedures through
advanced wire movements has the opportunity to reduce procedure time and
enhance patient outcomes."

Mark Toland, President and CEO of Corindus, stated, "FDA clearance of
this new software feature marks the first step on our path to full
autonomous navigation. Over the next several years, we will focus on
automating the techniques of world-class physicians to make them
available to every hospital with a vascular robotic program. We believe
artificial intelligence through procedural automation will increase the
value of robotics in the cath lab by reducing variability of treatment
and procedure time, and improving the overall quality of patient care."

About Corindus Vascular Robotics

Corindus
Vascular Robotics, Inc.
is a global technology leader in
robotic-assisted vascular interventions. The company's CorPath®
System is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and percutaneous vascular procedures.
During the procedure, the interventional cardiologist sits at a
radiation-shielded workstation to advance guide catheters, stents, and
guidewires with millimeter-by-millimeter precision. The workstation
allows the physician greater control and the freedom from wearing heavy
lead protective equipment that causes musculoskeletal injuries. CorPath
GRX is the second generation robotic-assisted PCI technology offering
enhancements to the platform by adding important key upgrades that
increase precision, improve workflow, and extend the capabilities and
range of procedures that can be performed robotically. With the CorPath
System, Corindus Vascular Robotics brings robotic precision to
interventional procedures to help optimize clinical outcomes and
minimize the costs associated with complications of improper stent
placement during manual procedures. Corindus stands behind its product
with its unique $1,000 hospital credit "One Stent Program." For
additional information, visit www.corindus.com,
and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical
or current facts are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of Corindus to be materially different from historical results or from
any future results or projections expressed or implied by such
forward-looking statements. Accordingly, readers should not place undue
reliance on any forward looking statements. In addition to statements
that explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as "believes," "belief," "expects," "estimates,"
"intends," "anticipates" or "plans" to be uncertain and forward-looking.
Forward-looking statements may include comments as to Corindus' beliefs
and expectations as to future events and trends affecting its business
and are necessarily subject to uncertainties, many of which are outside
Corindus' control.

Examples of such statements include statements that:

  • robotic automation can potentially extend the clinical capabilities
    of CorPath GRX in more complex procedures;
  • bringing consistency to interventional procedures through advanced
    wire movements may reduce procedure time and enhance patient outcomes;
  • the FDA clearance of the new software marks the first step on
    Corindus' path to total autonomous navigation;
  • Corindus will focus on automating the techniques of world-class
    physicians to make them available over the next several years to every
    hospital with a vascular robotic program; and
  • artificial intelligence through procedural automation will increase
    the value of robotics in the cath lab by reducing variability of
    treatment and procedure time, and improving the overall quality of
    patient care.

Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements are
described in the sections titled "Risk Factors" in the company's filings
with the Securities and Exchange Commission, including its most recent
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well
as reports on Form 8-K, including, but not limited to the following: the
rate of adoption of our CorPath System and the rate of use of our
cassettes; risks associated with market acceptance, including pricing
and reimbursement; our ability to enforce our intellectual property
rights; our need for additional funds to support our operations; our
ability to manage expenses and cash flow; factors relating to
engineering, regulatory, manufacturing, sales and customer service
challenges; potential safety and regulatory issues that could slow or
suspend our sales; and the effect of credit, financial and economic
conditions on capital spending by our potential customers. Forward
looking statements speak only as of the date they are made. Corindus
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More information
is available on Corindus' website at
http://www.corindus.com.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com